Bone Biologics Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.17next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release (Form 10-Q) | 13 Nov 2026 |
| FY 2026 Annual Earnings Release (Form 10-K) | 15 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Validated Shelf Life of rhNELL-1 Protein Product Quarterly29.0Target: Sufficient to support scaled manufacturing ahead of a pivotal study
Pilot Clinical Trial Patient Enrollment (Australia) QuarterlyTarget: 30 subjects
Cash and Cash Equivalents Balance Quarterly4.5MTarget: Sufficient to fund operations through fiscal year 2026
Watch Items
- First-in-Human Pilot Clinical Trial Progress in AustraliaTrigger: Completion of patient enrollment (up to 30 subjects) and initial safety/efficacy data readoutsAction: Evaluate clinical data to support regulatory filings and plan for a future pivotal study
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price falling below $1.00 for 30 consecutive business daysAction: Monitor closing bid price and consider strategic options, including a potential reverse stock split
- Cash Runway and Capital Raising ActivitiesTrigger: Cash reserves dropping below $1.5 million or runway extending less than 6 monthsAction: Utilize the existing At-The-Market (ATM) offering program or seek additional debt/equity financing
Research as of 20 Jun 2026